Generic Name and Formulations:
Fluocinolone acetonide 0.19mg; implant for intravitreal inj.
Indications for ILUVIEN:
Diabetic macular edema (DME) in patients who have been previously treated with a course of corticosteroids without a significant rise in intraocular pressure.
Give by intravitreal inj. See full labeling for administration.
Ocular or periocular infections. Glaucoma.
Monitor for increased intraocular pressure and endophthalmitis; may include check for perfusion of the optic nerve head immediately, tonometry within 30 mins, and biomicroscopy between 2–7 days post inj. Risk of secondary ocular infections (eg, bacterial, fungal, viral). History of ocular herpes simplex: not recommended. Risk of implant migration if absent or torn posterior capsule of the lens. Pregnancy (Cat.C). Nursing mothers.
Cataract development, increased intraocular pressure; injection-related effects (eg, endophthalmitis, eye inflammation, retinal detachments), others.
Single-use applicator—1 (w. needle)
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Light Therapy May Prevent Depression During Hospitalization Post-Transplant in Multiple Myeloma
- Re-treatment With Checkpoint Inhibitors in Some Patients with NSCLC May Be Feasible
- TNFi Not Linked to Increased Risk for Cancer Recurrence in Rheumatoid Arthritis
- IL-23 Drives Castration-Resistant Prostate Cancer
- Immediate Instillation of Mitomycin C Post-TURBT May Benefit All Patients with Bladder Cancer